Published in Br J Cancer on January 21, 2016
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol (2016) 1.89
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget (2016) 0.79
Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol (2017) 0.75
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer (2017) 0.75
Biomarkers to predict prognosis and response to checkpoint inhibitors. Int J Clin Oncol (2017) 0.75
Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population. Int J Clin Oncol (2017) 0.75
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. Front Oncol (2017) 0.75
Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. Breast Cancer (Auckl) (2017) 0.75
Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. Invest New Drugs (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 3.13
Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol (2000) 2.86
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol (2013) 1.65
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer (2012) 1.19
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer (2009) 1.15
Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer (2015) 0.85